Caladrius Biosciences : to Present at Upcoming July Conferences
July 07, 2016 at 07:25 am EDT
Share
BASKING RIDGE, N.J., July 7, 2016 - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ('Caladrius' or the 'Company'), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that the Company's leadership will present at the following upcoming July conferences:
Business of Regenerative Medicine: How to Build a Company
Date and Time: Monday, July 11, 2016, 2:00 PM ET
Website:http://hsci.harvard.edu/event/brm_2016
Venue: Harvard Business School, Cambridge, Massachusetts
Topic: Building the Future: Advanced Therapies & Scalability
Presenter: Robert A. Preti, PhD, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer of Caladrius; President, PCT
CIRM Bridges Meeting
Date and Time:Monday, July 18, 2016, 4:30 PM PT
Venue: Claremont Club & Spa, Berkeley, California
Topic: Succeeding for the Patient: Meeting Manufacturing Demands of Advanced Therapies
Presenter: Robert A. Preti, PhD, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer of Caladrius; President, PCT
Regenerative Medicine Crossroad
Date and Time:Thursday, July 28, 2016, 1:50 PM JST
Website: https://firm.or.jp/rmit/archives/162
Venue: Nihonbashi Life Science Building, Tokyo, Japan
Topic: Autologous CD34 Cell Therapy for Treatment of Critical Limb Ischemia Under PMDA Agreement
Presenter: Douglas W. Losordo, MD, Senior Vice President Clinical, Medical and Regulatory Affairs and Chief Medical Officer of Caladrius
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. Around the core expertise of PCT, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit www.caladrius.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the 'Risk Factors' described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC') on March 15, 2016, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.
Caladrius Biosciences Inc. published this content on 07 July 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 07 July 2016 11:25:01 UTC.
Original documenthttp://www.caladrius.com/press-release/upcoming-july-conferences/
Public permalinkhttp://www.publicnow.com/view/7720AC6134B70869DEC3246C715F0D39734EDC41
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.